Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BAT7104 |
| Synonyms | |
| Therapy Description |
BAT7104 is a bispecific antibody that targets both CD47 and PD-L1 (CD274), which may lead to increased phagocytosis and enhanced cytotoxic T-lymphocyte (CTL) response against tumor cells (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BAT7104 | BAT-7104|BAT 7104 | CD47 Antibody 31 Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 136 | BAT7104 is a bispecific antibody that targets both CD47 and PD-L1 (CD274), which may lead to increased phagocytosis and enhanced cytotoxic T-lymphocyte (CTL) response against tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05200013 | Phase I | BAT7104 | BAT7104 in Patients With Advanced Solid Tumours | Completed | AUS | 0 |